Leiden Dworak - Jul 21, 2023 Form 3 Insider Report for TScan Therapeutics, Inc. (TCRX)

Role: Chief Accounting Officer
Signature: /s/ Leiden Dworak
Stock symbol: TCRX
Transactions as of: Jul 21, 2023
Transactions value $: $0
Form type: 3
Date filed: 7/24/2023, 07:31 PM

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	TCRX	Voting Common Stock						5.69K	Jul 21, 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	TCRX	Stock Option (Right to Buy)							Jul 21, 2023	Voting Common Stock	37.5K	$2.90	Direct	F1
holding	TCRX	Stock Option (Right to Buy)							Jul 21, 2023	Voting Common Stock	28.8K	$1.81	Direct	F2
holding	TCRX	Stock Option (Right to Buy)							Jul 21, 2023	Voting Common Stock	164K	$2.49	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of April 4, 2022, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer.
F2	The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of February 2, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer.
F3	96,300 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of May 24, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. The remaining 67,500 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on February 2, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer, in each case subject to the Reporting Person's continued service at such time. This option was granted on May 24, 2023 subject to the approval of the Issuers' stockholders of an amendment to the TScan Therapeutics, Inc. 2021 Equity Incentive Plan, which was obtained on June 13, 2023.